2013
DOI: 10.1016/j.pnpbp.2013.07.023
|View full text |Cite
|
Sign up to set email alerts
|

Clozapine pre-treatment has a protracted hypolocomotor effect on the induction and expression of amphetamine sensitization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
4
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(4 citation statements)
references
References 41 publications
0
4
0
Order By: Relevance
“…The locomotor sensitisation protocol used in the present study was modified from Herrera et al . Horizontal locomotor activity was measured using an acrylic box (17 × 47 × 26 cm) in a behaviour test room.…”
Section: Methodsmentioning
confidence: 99%
“…The locomotor sensitisation protocol used in the present study was modified from Herrera et al . Horizontal locomotor activity was measured using an acrylic box (17 × 47 × 26 cm) in a behaviour test room.…”
Section: Methodsmentioning
confidence: 99%
“…Antipsychotic drugs primarily target dopamine receptor signaling at the dopamine D2 receptor. In animal models, antipsychotics that target D2 receptors induce dopamine neuron inactivation or block depolarization; treatment with amphetamine increases hyperactivity and other psychosis-relevant behaviors, and that treatment with the antipsychotic clozapine reverses these effects (Herrera et al, 2013; Valenti et al, 2011). Recently it has been suggested that hyperactivity of the DA signaling system may be related to reduced inhibitory neuron function in the hippocampus and ventral tegmentum, as selective reduction of parvalbumin interneurons in the hippocampus results in an increase in downstream dopamine neuron activity (Boley et al, 2014; Gilani et al, 2014).…”
Section: Introductionmentioning
confidence: 99%
“…These observations are in line with the ability of chronic treatment with OLA to alleviate AMPH-induced hyperlocomotion in sensitized mice [ 33 ]. By contrast, repeated administration of CLZ does not attenuate MAP-induced hyperlocomotion [ 34 , 35 ] or reverse AMPH-induced hyperlocomotion [ 36 ].…”
Section: Discussionmentioning
confidence: 99%